Until validated tools that provide useful information to identify patients who might not require chemotherapy are developed, most patients with high-risk or node-positive ER+/HER2+ early breast cancer require chemotherapy with trastuzumab and pertuzumab. Here, ERBB2 is linked to breast carcinoma.